Skip to main content
N

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 91 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Phase 1 IRX-616a Trial Advances to Final Cohort 2 pages 120.6KB
Regulatory Filings Classification · 0% confidence The document is a corporate press release providing an operational update on a Phase 1 clinical trial milestone. It contains no financial results, no request for votes, no share transactions, no governance detail, and no formal regulatory form. It is not an attached report or presentation but a generic announcement of progress. Therefore it falls under the fallback category for miscellaneous regulatory/operational announcements: Regulatory Filings (RNS).
2026-04-27 English
US Policy Market Advancement Supports SRX-25 TRD Treatment 4 pages 221.7KB
Regulatory Filings Classification · 0% confidence The document is a press release/update by Nexalis Therapeutics announcing recent U.S. policy developments and their impact on the company’s SRX-25 program. It does not contain financial results (so not an Earnings Release or Interim/Quarterly Report), nor is it an investor slide deck (Investor Presentation). It is not a capital raising announcement, board change, or any specialized regulatory filing category. It serves as a general corporate announcement, making Regulatory Filings (RNS) the appropriate fallback category.
2026-04-22 English
Significant Milestone - First Patient Screened IRX-211 Ph2 3 pages 189.1KB
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the clinical milestone of first patient screening in a Phase 2 trial of IRX-211. It does not present financial results (Earnings Release), regulatory form data, management changes, share transactions, or dividends. It is not an investor presentation or formal report itself, but a general update on business progress. Therefore it falls into the fallback category of general regulatory announcement or miscellaneous filing: Regulatory Filings (RNS).
2026-04-19 English
Phase 1 IRX-616a Trial Advances - Positive Safety Review 2 pages 141.2KB
Regulatory Filings Classification · 1% confidence The document is an ASX press release providing an operational update on the Phase 1 clinical trial of IRX-616a. It contains no financial results, fundraising, dividend, governance changes, or call transcript content. It does not fit any specific financial filing definition (e.g., Annual/Interim Report, Earnings Release, M&A, Capital Update). As a general company announcement, it falls under the fallback category for miscellaneous regulatory filings.
2026-04-16 English
2025 Corporate Governance Statement and 4G 32 pages 745.4KB
Regulatory Filings
2026-03-30 English
2025 Annual Report 48 pages 2.4MB
Regulatory Filings
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.